In the past week, GSK stock has gone up by 0.37%, with a monthly decline of -4.00% and a quarterly plunge of -0.88%. The volatility ratio for the week is 1.13%, and the volatility levels for the last 30 days are 1.55% for GSK Plc ADR The simple moving average for the last 20 days is -4.01% for GSK stock, with a simple moving average of 3.01% for the last 200 days.
Is It Worth Investing in GSK Plc ADR (NYSE: GSK) Right Now?
The price-to-earnings ratio for GSK Plc ADR (NYSE: GSK) is 19.94x, which is above its average ratio. Moreover, the 36-month beta value for GSK is 0.50. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 5 as “hold,” and 1 as “sell.”
The public float for GSK is 2.02B and currently, short sellers hold a 0.81% of that float. On July 01, 2025, GSK’s average trading volume was 5.53M shares.
GSK) stock’s latest price update
The stock price of GSK Plc ADR (NYSE: GSK) has plunged by -0.47 when compared to previous closing price of 38.58, but the company has seen a 0.37% gain in its stock price over the last five trading sessions. reuters.com reported 2025-06-27 that Democratic U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline’s decision to discontinue a widely used asthma inhaler for children.
Analysts’ Opinion of GSK
Exane BNP Paribas, on the other hand, stated in their research note that they expect to see GSK reach a price target of $35.25. The rating they have provided for GSK stocks is “Neutral” according to the report published on April 15th, 2025.
GSK Trading at -1.03% from the 50-Day Moving Average
After a stumble in the market that brought GSK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.04% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GSK starting from GSK plc, who purchase 2,791,930 shares at the price of $8.00 back on Sep 27 ’24. After this action, GSK plc now owns 16,775,691 shares of GSK Plc ADR, valued at $22,335,440 using the latest closing price.
Stock Fundamentals for GSK
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.72 for the gross margin
The net margin for GSK Plc ADR stands at 0.1. The total capital return value is set at 0.13. Equity return is now at value 22.26, with 5.23 for asset returns.
Based on GSK Plc ADR (GSK), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at 0.35. The debt to equity ratio resting at 1.3. The interest coverage ratio of the stock is 7.65.
Currently, EBITDA for the company is 6.67 billion with net debt to EBITDA at 1.7. When we switch over and look at the enterprise to sales, we see a ratio of 2.23. The receivables turnover for the company is 4.2for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.87.
Conclusion
To wrap up, the performance of GSK Plc ADR (GSK) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
